ACER
Acer Therapeutics Inc
Acer Therapeutics Inc
$ACER Reports Launch Details for OLPRUVA and UCD Patient Support
Acer Therapeutics presented data from a healthcare provider survey on Urea Cycle Disorders (UCDs) and announced progress on the launch activities of their nitrogen-binding medication OLPRUVA. They also introduced the OLPRUVA Navigator to aid UCD patients with support and adherence to treatment. The company plans to invest in additional solutions to improve patient outcomes. CEO Chris Schelling expressed pride in offering a responsibly priced treatment option and working closely with the UCD community. The press release includes forward-looking statements regarding financing, drug development risks, and regulatory actions.
6d ago
$ACER